DAY ONE BIOPHARMACEUTICALS I's ticker is DAWN and the CUSIP is 23954D109. A total of 123 filers reported holding DAY ONE BIOPHARMACEUTICALS I in Q1 2023. The put-call ratio across all filers is 0.46 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $119,000 | +101.7% | 9,721 | +99.2% | 0.00% | – |
| Q2 2023 | $59,000 | +59.5% | 4,881 | +74.1% | 0.00% | – |
| Q1 2023 | $37,000 | -60.2% | 2,804 | -35.4% | 0.00% | – |
| Q4 2022 | $93,000 | +210.0% | 4,339 | +187.9% | 0.00% | – |
| Q3 2022 | $30,000 | +36.4% | 1,507 | +18.1% | 0.00% | – |
| Q2 2022 | $22,000 | -12.0% | 1,276 | -49.8% | 0.00% | – |
| Q1 2022 | $25,000 | -54.5% | 2,542 | -23.1% | 0.00% | – |
| Q4 2021 | $55,000 | +66.7% | 3,305 | +140.2% | 0.00% | – |
| Q3 2021 | $33,000 | – | 1,376 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners XI LLC | 2,548,403 | $54,841,633 | 43.06% |
| PATHWAY CAPITAL MANAGEMENT, LP | 995,686 | $21,427,163 | 38.24% |
| Atlas Venture Life Science Advisors, LLC | 7,568,317 | $162,870,182 | 19.62% |
| RA Capital Management | 7,040,622 | $151,514,185 | 3.07% |
| COMMODORE CAPITAL LP | 739,661 | $15,918 | 2.40% |
| GREAT POINT PARTNERS LLC | 544,451 | $11,716,586 | 2.30% |
| Nicholas Investment Partners, LP | 786,554 | $16,926,642 | 1.48% |
| Boxer Capital, LLC | 1,189,943 | $25,607,573 | 1.35% |
| Parkman Healthcare Partners LLC | 224,483 | $4,830,874 | 1.29% |
| Cheyne Capital Management (UK) LLP | 27,223 | $585,839 | 1.02% |